Scholarlink

Introduction <p>This study evaluated real-world cassette use and cost of levodopa-carbidopa intestinal gel (LCIG; 2000&#xa0;mg levodopa equivalent dose [LED]) and levodopa-entacapone-carbidopa intestinal gel (LECIG; 1250&#xa0;mg LED) pump treatments among patients with advanced Parkinson’s disease (PD) in Sweden.</p> Methods <p>This was a non-interventional, longitudinal, retrospective, comparative study of patients with PD using data from Swedish national registries (National Patient Register [NPR] and Prescribed Drug Register [PDR]). Patients were enrolled in the study from January 1, 2017, to May 31, 2022 (NPR) or June 30, 2022 (PDR). Patients had two or more dispensed prescription records for either LCIG (January 1, 2017, onward) or LECIG (January 1, 2019, onward) and at least one diagnosis of PD on or before their first dispensed prescription. Average daily cassette use, costs (Swedish krona [SEK]), treatment persistence, and treatment patterns were assessed.</p> Results <p>Overall, 419 patients (LCIG, <i>n</i> = 276; LECIG, <i>n</i> = 180; both LCIG and LECIG, <i>n</i> = 37 [cohorts not mutually exclusive]) were included. Mean (SD) daily cassette use was significantly higher for LECIG than for LCIG: 1.28 (0.40) versus 1.09 (0.28) at 1–365&#xa0;days (<i>p</i> &lt; 0.0001). LECIG use was higher than LCIG at 365&#xa0;days regardless of prior levodopa pump experience. The overall cost of LECIG was higher than that of LCIG; the highest cost difference between treatments was at 365&#xa0;days (daily cost mean [SD], LCIG 991.23 [259.43] SEK vs. LECIG 1100.23 [341.04] SEK; <i>p</i> = 0.0036). Annual per-patient costs were approximately 40,000 SEK higher for LECIG versus LCIG. More patients discontinued LECIG than LCIG treatment, with 68.9% and 75.2% of those receiving LECIG and LCIG, respectively, still on treatment at 365&#xa0;days.</p> Conclusion <p>Real-world data show that the number of dispensed cassettes and overall treatment costs are higher for LECIG than LCIG treatment among patients with advanced PD in Sweden.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson’s Disease: A Swedish Study on Real-World Use and Costs

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月10日

查看全文
  • Per Odin,
  • Christoffer Tærud,
  • Jenny Samuelsson,
  • Emma Sabelström,
  • Jeanette Lagerlund,
  • Jonatan Freilich,
  • M. Natalia Stelmaszuk

摘要

Introduction

This study evaluated real-world cassette use and cost of levodopa-carbidopa intestinal gel (LCIG; 2000 mg levodopa equivalent dose [LED]) and levodopa-entacapone-carbidopa intestinal gel (LECIG; 1250 mg LED) pump treatments among patients with advanced Parkinson’s disease (PD) in Sweden.

Methods

This was a non-interventional, longitudinal, retrospective, comparative study of patients with PD using data from Swedish national registries (National Patient Register [NPR] and Prescribed Drug Register [PDR]). Patients were enrolled in the study from January 1, 2017, to May 31, 2022 (NPR) or June 30, 2022 (PDR). Patients had two or more dispensed prescription records for either LCIG (January 1, 2017, onward) or LECIG (January 1, 2019, onward) and at least one diagnosis of PD on or before their first dispensed prescription. Average daily cassette use, costs (Swedish krona [SEK]), treatment persistence, and treatment patterns were assessed.

Results

Overall, 419 patients (LCIG, n = 276; LECIG, n = 180; both LCIG and LECIG, n = 37 [cohorts not mutually exclusive]) were included. Mean (SD) daily cassette use was significantly higher for LECIG than for LCIG: 1.28 (0.40) versus 1.09 (0.28) at 1–365 days (p < 0.0001). LECIG use was higher than LCIG at 365 days regardless of prior levodopa pump experience. The overall cost of LECIG was higher than that of LCIG; the highest cost difference between treatments was at 365 days (daily cost mean [SD], LCIG 991.23 [259.43] SEK vs. LECIG 1100.23 [341.04] SEK; p = 0.0036). Annual per-patient costs were approximately 40,000 SEK higher for LECIG versus LCIG. More patients discontinued LECIG than LCIG treatment, with 68.9% and 75.2% of those receiving LECIG and LCIG, respectively, still on treatment at 365 days.

Conclusion

Real-world data show that the number of dispensed cassettes and overall treatment costs are higher for LECIG than LCIG treatment among patients with advanced PD in Sweden.